Biostatistics Quiz: Null And Alternative Hypotheses

20 questions · exam conditions

0:00

Null And Alternative HypothesesQuestion 1 of 20

In a study comparing mean cholesterol levels between two populations, Population A (urban) and Population B (rural), researchers hypothesize that urban living leads to higher cholesterol levels. If $μ_A$ and $μ_B$ represent the population means, what hypotheses should be tested?

H_0: μ_A - μ_B = 0

;

H_1: μ_A - μ_B ≠ 0

H_0: μ_A - μ_B ≤ 0

;

H_1: μ_A - μ_B > 0

H_0: μ_A = μ_B

;

H_1: μ_A > μ_B

H_0: μ_A ≥ μ_B

;

H_1: μ_A < μ_B

H_0: μ_A < μ_B

;

H_1: μ_A ≥ μ_B

← Back to quizzes

Biostatistics Quiz

Biostatistics Quiz: Null And Alternative Hypotheses

Practice Null And Alternative Hypotheses in Biostatistics with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Null And Alternative Hypotheses, giving you a quick way to practice the rules, question types, and explanations that matter most for Biostatistics.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

$H_0: μ_A - μ_B = 0$ ; $H_1: μ_A - μ_B ≠ 0$
$H_0: μ_A - μ_B ≤ 0$ ; $H_1: μ_A - μ_B > 0$ (correct answer)
$H_0: μ_A = μ_B$ ; $H_1: μ_A > μ_B$
$H_0: μ_A ≥ μ_B$ ; $H_1: μ_A < μ_B$
$H_0: μ_A < μ_B$ ; $H_1: μ_A ≥ μ_B$

Explanation: When you encounter hypothesis testing questions, the key is translating the research question into proper null and alternative hypotheses. The research hypothesis here states that "urban living leads to higher cholesterol levels," which means researchers expect

μ_A > μ_B

. In hypothesis testing, the null hypothesis (

H_0

) represents the status quo or "no effect" position, while the alternative hypothesis (

H_1

) represents what the researchers are trying to prove. Since researchers hypothesize that urban populations have higher cholesterol, they want to test whether

μ_A > μ_B

. The null hypothesis must therefore represent the opposite: that urban populations do not have higher cholesterol levels, or

μ_A ≤ μ_B

. Answer B correctly sets up this one-tailed test:

H_0: μ_A - μ_B ≤ 0

(urban cholesterol is less than or equal to rural) and

H_1: μ_A - μ_B > 0

(urban cholesterol is greater than rural). Answer A represents a two-tailed test, which would be appropriate if researchers simply wanted to test whether the populations differ in any direction, not specifically that urban is higher. Answer C uses correct notation but places the directional hypothesis in

H_0

instead of

H_1

, which violates hypothesis testing principles. Answer D tests the opposite direction entirely, hypothesizing that rural populations have higher cholesterol. Study tip: Always identify the research direction first, then set up

H_1

to match that direction and

H_0

as its complement. The alternative hypothesis should reflect what the researchers are trying to prove, not the null position.

Question 2

A pharmaceutical company claims that their new antihypertensive medication reduces systolic blood pressure by more than 10 mmHg on average. In designing a clinical trial to test this claim, what should be the null and alternative hypotheses if μ represents the mean reduction in systolic blood pressure?

$H_0: μ ≤ 10$ ; $H_1: μ > 10$ (correct answer)
$H_0: μ = 10$ ; $H_1: μ ≠ 10$
$H_0: μ ≥ 10$ ; $H_1: μ < 10$
$H_0: μ > 10$ ; $H_1: μ ≤ 10$
$H_0: μ < 10$ ; $H_1: μ ≥ 10$

Explanation: When you encounter hypothesis testing problems involving company claims or manufacturer assertions, remember that the null hypothesis always represents the status quo or the opposite of what you're trying to prove. The company wants to demonstrate their drug is better than a 10 mmHg reduction, so you're testing whether they can prove superiority. The correct approach is option A:

H_0: μ ≤ 10

and

H_1: μ > 10

. The null hypothesis assumes the drug is not superior (reduces blood pressure by 10 mmHg or less), while the alternative hypothesis represents what the company wants to prove (reduction greater than 10 mmHg). This is a one-tailed test because we're specifically testing for superiority in one direction. Option B (

H_0: μ = 10

;

H_1: μ ≠ 10

) sets up a two-tailed test that would detect any difference from exactly 10 mmHg, but doesn't address the specific claim of superiority. Option C (

H_0: μ ≥ 10

;

H_1: μ < 10

) reverses the logic entirely—it would test whether the drug performs worse than claimed. Option D (

H_0: μ > 10

;

H_1: μ ≤ 10

) incorrectly places the claim in the null hypothesis, which violates the fundamental principle that the null represents what you assume until proven otherwise. Study tip: In clinical trials testing superiority claims, always put the "no effect" or "not superior" condition in

H_0

and the desired outcome in

H_1

. The burden of proof lies with whoever makes the claim.

Question 3

A quality control manager wants to ensure that the mean weight of medication tablets does not deviate from the target weight of 250 mg by more than 5 mg in either direction. The production process will be considered acceptable if the mean weight is between 245 mg and 255 mg. What hypotheses should be tested?

$H_0: μ = 250$ ; $H_1: μ ≠ 250$
$H_0: 245 ≤ μ ≤ 255$ ; $H_1: μ < 245$ or $μ > 255$
$H_0: μ < 245$ or $μ > 255$ ; $H_1: 245 ≤ μ ≤ 255$
$H_0: |μ - 250| ≤ 5$ ; $H_1: |μ - 250| > 5$ (correct answer)
$H_0: μ ≥ 245$ and $μ ≤ 255$ ; $H_1: μ < 245$ or $μ > 255$

Explanation: When you encounter quality control problems with acceptable ranges, you're dealing with equivalence testing rather than traditional hypothesis testing. The key insight is understanding what the null and alternative hypotheses represent in terms of the manufacturing decision. The correct approach is Answer D:

H_0: |μ - 250| ≤ 5

;

H_1: |μ - 250| > 5

. This formulation directly captures the quality control scenario. The null hypothesis states that the mean weight is within the acceptable range (within 5 mg of the target), while the alternative hypothesis represents the undesirable situation where the process has deviated too far from target. The absolute value notation

|μ - 250| ≤ 5

is mathematically equivalent to

245 ≤ μ ≤ 255

, but emphasizes the deviation concept. Answer A represents a traditional two-tailed test for whether the mean equals exactly 250 mg, but this doesn't address the acceptable range concept that's central to quality control. Answer B has the logic backwards - it treats being within specifications as the null hypothesis, which would make statistical sense but doesn't align with quality control decision-making where we want to detect deviations from acceptable performance. Answer C also has backwards logic, treating the undesirable state (out of specification) as the null hypothesis. Study tip: In quality control contexts, the null hypothesis typically represents the acceptable or desired state of the process, while the alternative represents the condition requiring corrective action. Look for formulations that test whether parameters fall outside acceptable limits.

Question 4

A researcher is investigating whether a new therapy increases the median survival time for cancer patients. Historical data shows a median survival time of 18 months. The researcher will only recommend the therapy if there's evidence it provides improvement. If M represents the median survival time with the new therapy, what hypotheses should be formulated?

$H_0: M = 18$ ; $H_1: M ≠ 18$
$H_0: M ≤ 18$ ; $H_1: M > 18$ (correct answer)
$H_0: M ≥ 18$ ; $H_1: M < 18$
$H_0: M > 18$ ; $H_1: M ≤ 18$
$H_0: M < 18$ ; $H_1: M ≥ 18$

Explanation: When you encounter hypothesis testing problems, the key is understanding what the researcher wants to prove and how hypothesis testing is structured. The researcher seeks evidence that the new therapy improves survival time, meaning they want to show it increases the median beyond the historical 18 months. In hypothesis testing, you always put the status quo or "no effect" condition in the null hypothesis (

H_0

), while the alternative hypothesis (

H_1

) contains what you're trying to prove. Since the researcher will only recommend the therapy if there's evidence of improvement, they need to prove

M > 18

. This means

H_1: M > 18

(what they want to demonstrate) and

H_0: M ≤ 18

(the assumption that the therapy doesn't improve survival or makes it worse). Looking at the wrong answers: Choice A (

H_0: M = 18

;

H_1: M ≠ 18

) sets up a two-tailed test that would detect any difference from 18 months, but the researcher specifically wants to show improvement, not just any change. Choice C (

H_0: M ≥ 18

;

H_1: M < 18

) tests whether the therapy worsens survival, which is the opposite of what's needed. Choice D (

H_0: M > 18

;

H_1: M ≤ 18

) incorrectly puts the desired outcome in the null hypothesis. The correct answer is B because it properly structures a one-tailed test where rejecting

H_0

provides evidence supporting the therapy's effectiveness. Study tip: Remember that

H_1

always contains what you're trying to prove, while

H_0

represents the skeptical position or status quo.

Question 5

In a bioequivalence study, researchers need to demonstrate that a generic drug has the same mean bioavailability as the brand-name drug. Regulatory guidelines require showing that the ratio of mean bioavailabilities is between 0.8 and 1.25. If R represents this ratio (generic/brand), how should the hypotheses be structured for regulatory approval?

$H_0: R = 1$ ; $H_1: R ≠ 1$
$H_0: 0.8 ≤ R ≤ 1.25$ ; $H_1: R < 0.8$ or $R > 1.25$
$H_0: R < 0.8$ or $R > 1.25$ ; $H_1: 0.8 ≤ R ≤ 1.25$ (correct answer)
$H_0: R ≤ 0.8$ or $R ≥ 1.25$ ; $H_1: 0.8 < R < 1.25$
$H_0: R = 0.8$ or $R = 1.25$ ; $H_1: 0.8 < R < 1.25$

Explanation: Bioequivalence studies use equivalence testing, which flips traditional hypothesis testing logic. Instead of trying to prove a difference exists, you're trying to prove that two treatments are practically equivalent within specified bounds. In equivalence testing, the null hypothesis represents what you want to reject - that the treatments are NOT equivalent (outside acceptable limits). The alternative hypothesis represents what you want to prove - that they ARE equivalent (within acceptable limits). Since regulatory approval requires demonstrating bioequivalence, you need to structure hypotheses so that rejecting

H_0

leads to approval. Option C correctly sets

H_0: R < 0.8

R > 1.25

(non-equivalence) and

H_1: 0.8 ≤ R ≤ 1.25

(equivalence). By rejecting this null hypothesis, you demonstrate the ratio falls within the acceptable range, supporting regulatory approval. Option A uses traditional two-sided testing, which only tests if the ratio differs from 1, not whether it's within the regulatory range of 0.8-1.25. Option B reverses the logic - it makes equivalence the null hypothesis, which would require proving non-equivalence for rejection rather than proving equivalence. Option D uses incorrect inequality symbols and doesn't properly represent the equivalence bounds as a continuous range. Remember: In equivalence testing, always put what you want to disprove (non-equivalence) as

H_0

and what you want to prove (equivalence within bounds) as

H_1

. This ensures that statistical significance leads to the desired regulatory conclusion.

Question 6

In a clinical trial, researchers want to test whether a new treatment reduces the proportion of patients who experience treatment failure. Historical data shows a failure rate of 0.30. The treatment will be considered effective only if the failure rate drops below 0.25. If p represents the failure rate with the new treatment, what hypotheses should be tested to determine treatment effectiveness?

$H_0: p = 0.30$ ; $H_1: p ≠ 0.30$
$H_0: p ≥ 0.25$ ; $H_1: p < 0.25$ (correct answer)
$H_0: p ≤ 0.25$ ; $H_1: p > 0.25$
$H_0: p = 0.25$ ; $H_1: p > 0.25$
$H_0: p ≥ 0.30$ ; $H_1: p < 0.30$

Explanation: When designing hypothesis tests for clinical effectiveness, you need to carefully consider what question you're actually trying to answer. The key insight here is that the researchers aren't just testing whether the new treatment is different from historical data—they want to prove the treatment meets a specific effectiveness threshold. The correct approach is option B:

H_0: p ≥ 0.25

;

H_1: p < 0.25

. This directly tests whether the failure rate drops below the 0.25 threshold that defines treatment effectiveness. The null hypothesis assumes the treatment is NOT effective (failure rate remains at or above 0.25), while the alternative hypothesis represents what the researchers hope to prove—that the treatment is effective with a failure rate below 0.25. Option A tests whether the new treatment differs from historical rates (0.30) but doesn't address the effectiveness threshold of 0.25. Even if you rejected this null hypothesis, you wouldn't know if the treatment meets the effectiveness criteria. Option C reverses the hypotheses, making it a test to prove the treatment is ineffective—the opposite of what researchers want to demonstrate. Option D only tests against the exact threshold value (0.25) rather than testing whether the rate falls below it, which doesn't properly frame the effectiveness question. Study tip: In clinical effectiveness studies, always identify the threshold that defines "success" and set up your hypotheses to test whether that threshold is met. The alternative hypothesis should reflect what you're trying to prove, and the null should represent the "no effect" or "not effective" scenario.

Question 7

In a study of vaccine efficacy, researchers want to test whether a new vaccine provides at least 70% protection against infection. The vaccine efficacy is calculated as (1 - relative risk). If E represents the vaccine efficacy, what hypotheses should be tested to evaluate whether the vaccine meets the minimum efficacy requirement?

$H_0: E = 0.70$ ; $H_1: E ≠ 0.70$
$H_0: E ≥ 0.70$ ; $H_1: E < 0.70$
$H_0: E ≤ 0.70$ ; $H_1: E > 0.70$ (correct answer)
$H_0: E < 0.70$ ; $H_1: E ≥ 0.70$
$H_0: E > 0.70$ ; $H_1: E ≤ 0.70$

Explanation: When you encounter vaccine efficacy studies, you're dealing with one-tailed hypothesis tests where researchers want to prove a treatment meets or exceeds a minimum standard. The key is identifying what the researchers are trying to demonstrate versus what they assume under the null hypothesis. In this study, researchers want to prove the vaccine provides at least 70% protection. In hypothesis testing, you set up the null hypothesis as the opposite of what you're trying to prove. Since they want to show

E ≥ 0.70

, the null hypothesis should assume

E ≤ 0.70

(the vaccine doesn't meet the standard), and the alternative hypothesis should be

E > 0.70

(the vaccine exceeds the minimum requirement). This makes option C correct. Option A sets up a two-tailed test (

E ≠ 0.70

) when you need a one-tailed test, and tests for exact equality rather than a minimum threshold. Option B reverses the logic—it assumes the vaccine works well under the null hypothesis, which contradicts the fundamental principle that null hypotheses typically represent "no effect" or "doesn't meet standards." Option D also has the hypotheses backwards and uses incorrect inequality symbols. Remember this pattern: when a study aims to prove something "meets or exceeds" a standard, set your null hypothesis as "fails to meet the standard" (≤) and your alternative as "exceeds the standard" (>). The researchers will try to reject the null to prove their treatment works.

Question 8

A researcher is testing whether a new diagnostic test has better sensitivity than the current standard test. The current test has a sensitivity of 0.85. The new test will be adopted only if it demonstrates superior sensitivity. If S represents the sensitivity of the new test, what hypotheses should guide the adoption decision?

$H_0: S = 0.85$ ; $H_1: S ≠ 0.85$
$H_0: S ≤ 0.85$ ; $H_1: S > 0.85$ (correct answer)
$H_0: S ≥ 0.85$ ; $H_1: S < 0.85$
$H_0: S > 0.85$ ; $H_1: S ≤ 0.85$
$H_0: S < 0.85$ ; $H_1: S ≥ 0.85$

Explanation: When evaluating whether to adopt a new diagnostic test, you're dealing with a one-tailed hypothesis test that directly reflects the decision-making context. The key insight is that the new test will only be adopted if it's superior to the current standard—not just different from it. The correct approach is option B:

H_0: S ≤ 0.85

;

H_1: S > 0.85

. This setup perfectly aligns with the adoption decision. The null hypothesis represents the status quo—that the new test is no better than (or worse than) the current standard. The alternative hypothesis represents what you need to prove: that the new test has superior sensitivity. You'll only reject the null and adopt the new test if you have strong evidence that its sensitivity exceeds 0.85. Option A uses a two-tailed test (

H_1: S ≠ 0.85

), which would be inappropriate because you don't care if the new test is merely different—it must be better. Option C reverses the hypotheses entirely, testing whether the new test is worse, which contradicts the research goal. Option D puts the superiority claim in the null hypothesis (

H_0: S > 0.85

), which is backwards since you need evidence to support superiority, not assume it. Remember this pattern: when testing for improvement or superiority in biostatistics, your alternative hypothesis should reflect the direction of improvement you're trying to demonstrate. The null hypothesis represents "no improvement" or the current standard, while the alternative represents the improvement you hope to prove.

Question 9

In a multi-center clinical trial, researchers want to test whether the treatment effect (measured as mean reduction in symptoms) is consistent across all centers versus having significant variation between centers. If $σ²_c$ represents the variance in treatment effects between centers, what hypotheses should be tested?

$H_0: σ²_c = 0$ ; $H_1: σ²_c ≠ 0$
$H_0: σ²_c > 0$ ; $H_1: σ²_c = 0$
$H_0: σ²_c = 0$ ; $H_1: σ²_c > 0$ (correct answer)
$H_0: σ²_c ≤ 0$ ; $H_1: σ²_c > 0$
$H_0: σ²_c ≥ 0$ ; $H_1: σ²_c < 0$

Explanation: When you encounter questions about variance components in multi-center trials, you're dealing with hypothesis testing for variance parameters. The key insight is understanding what each hypothesis represents and recognizing the directional nature of variance testing. In this scenario, researchers want to determine if treatment effects vary significantly between centers. If

σ²_c = 0

, this means there's no variation between centers—the treatment effect is consistent everywhere. If

σ²_c > 0

, there's meaningful variation between centers in how well the treatment works. The correct approach is C:

H_0: σ²_c = 0

versus

H_1: σ²_c > 0

. The null hypothesis assumes no between-center variation (homogeneity), while the alternative suggests significant heterogeneity exists. Since variance cannot be negative, we use a one-sided alternative hypothesis testing whether variance is greater than zero. A is incorrect because it uses a two-sided alternative (

σ²_c ≠ 0

), but variance components are always non-negative, making the "less than zero" portion meaningless. B reverses the logic entirely—you never assume variance exists under the null hypothesis when testing for its presence. D includes

σ²_c ≤ 0

in the null hypothesis, which is nonsensical since variance cannot be negative. Study tip: For variance component testing, always remember that variance is non-negative, so your null hypothesis should assume no variation (

σ² = 0

) and your alternative should test for positive variation (

σ² > 0

). This creates a one-sided test in the positive direction.

Question 10

In a dose-response study, researchers want to test whether increasing the dose of a medication leads to a positive linear relationship between dose (x) and therapeutic effect (y). They specifically want to test if the slope of the regression line is positive. If β represents the population slope coefficient, what hypotheses should be tested?

$H_0: β = 0$ ; $H_1: β ≠ 0$
$H_0: β ≤ 0$ ; $H_1: β > 0$ (correct answer)
$H_0: β ≥ 0$ ; $H_1: β < 0$
$H_0: β < 0$ ; $H_1: β ≥ 0$
$H_0: β > 0$ ; $H_1: β ≤ 0$

Explanation: When you encounter hypothesis testing in regression analysis, you need to carefully match your research question to the appropriate directional test. This study specifically wants to test whether there's a positive linear relationship, meaning they have a directional hypothesis about the slope. The correct approach is option B:

H_0: β ≤ 0

;

H_1: β > 0

. This is a one-tailed test where the null hypothesis states that the slope is zero or negative (no positive relationship), while the alternative hypothesis states what the researchers want to prove - that the slope is positive. This setup allows you to conclude that increasing dose leads to increased therapeutic effect if you reject the null. Option A (

H_0: β = 0

;

H_1: β ≠ 0

) is a two-tailed test that only tests whether there's any linear relationship, not specifically a positive one. You could reject this null even with a negative slope, which doesn't answer the research question. Option C (

H_0: β ≥ 0

;

H_1: β < 0

) tests for a negative relationship, which is the opposite of what researchers want to demonstrate. Option D (

H_0: β < 0

;

H_1: β ≥ 0

) has the null hypothesis claiming the slope is negative, which is unusual since we typically put the status quo or "no effect" condition in the null hypothesis. Study tip: In regression hypothesis testing, always put what you want to prove in the alternative hypothesis. For directional research questions like "does X increase Y?", use one-tailed tests with the desired direction in

H_1

Question 11

A researcher is studying whether environmental exposure increases the risk of a particular disease. The baseline risk in unexposed populations is 0.05. The researcher will recommend public health interventions only if the exposed population has a risk that is significantly higher than baseline. If p represents the disease risk in the exposed population, what hypotheses should guide the intervention recommendation?

$H_0: p = 0.05$ ; $H_1: p ≠ 0.05$
$H_0: p ≤ 0.05$ ; $H_1: p > 0.05$ (correct answer)
$H_0: p ≥ 0.05$ ; $H_1: p < 0.05$
$H_0: p > 0.05$ ; $H_1: p ≤ 0.05$
$H_0: p < 0.05$ ; $H_1: p ≥ 0.05$

Explanation: When you encounter hypothesis testing questions involving public health recommendations, focus on what action the researcher wants to take and what evidence would justify that action. The key is matching the alternative hypothesis to the specific concern being investigated. Here, the researcher will only recommend interventions if the exposed population has significantly higher risk than the baseline of 0.05. This means you're looking for evidence of increased risk, not just any difference from baseline. This calls for a one-tailed test where the alternative hypothesis represents the condition that would trigger action. Option B correctly sets up this scenario. The null hypothesis

H_0: p ≤ 0.05

represents the "no action needed" state - either no increase in risk or baseline risk. The alternative hypothesis

H_1: p > 0.05

represents the specific condition that would justify intervention: significantly elevated risk above baseline. Option A uses a two-tailed test (

H_1: p ≠ 0.05

), which would trigger intervention for either increased or decreased risk. Since decreased risk wouldn't warrant public health intervention, this doesn't match the research question. Option C has the hypotheses backwards - it would look for evidence that risk is lower than baseline, which contradicts the stated concern about environmental exposure increasing risk. Option D incorrectly places the action-triggering condition (

p > 0.05

) in the null hypothesis, which would assume increased risk is the default state requiring evidence to disprove. Study tip: In hypothesis testing for public health, always align your alternative hypothesis with the condition that would prompt action or intervention. The null hypothesis represents the status quo or "no action needed" scenario.

Question 12

A researcher wants to test whether the variance in blood glucose measurements from a new glucose meter is significantly different from the variance of the standard meter, which is 25 mg²/dL². The new meter should be adopted only if it shows improved precision (lower variance). If $σ²$ represents the variance of the new meter, what hypotheses should be tested?

$H_0: σ² = 25$ ; $H_1: σ² ≠ 25$
$H_0: σ² ≥ 25$ ; $H_1: σ² < 25$ (correct answer)
$H_0: σ² ≤ 25$ ; $H_1: σ² > 25$
$H_0: σ² > 25$ ; $H_1: σ² ≤ 25$
$H_0: σ² < 25$ ; $H_1: σ² ≥ 25$

Explanation: When you encounter hypothesis testing questions about variance, you need to carefully distinguish between two-tailed tests (testing for any difference) and one-tailed tests (testing for a specific direction of difference). The key here is understanding what the researcher actually wants to demonstrate. The correct answer is B because the researcher has a specific goal: to adopt the new meter only if it shows "improved precision," meaning lower variance. This creates a directional research question. In hypothesis testing, you set up the null hypothesis as the opposite of what you're trying to prove. Since the researcher wants to demonstrate that the new meter has lower variance (

σ² < 25

), the null hypothesis should state that the variance is greater than or equal to 25 (

H_0: σ² ≥ 25

), with the alternative being

H_1: σ² < 25

. Answer A represents a two-tailed test, which would be appropriate if you simply wanted to detect any difference in variance, not specifically an improvement. This doesn't match the researcher's stated goal of only adopting the meter if it's better. Answer C has the hypotheses backwards - it would test whether the new meter is worse (higher variance), which contradicts the research objective. Answer D incorrectly places the inequality in the null hypothesis, violating the standard convention that null hypotheses typically contain equality. Study tip: Remember that one-tailed tests are used when you have a specific directional prediction. Always set your null hypothesis as the opposite of what you're trying to prove, and include equality in the null hypothesis.

Question 13

A researcher wants to test whether the median time to recovery differs between two treatment groups. Group A receives standard care and Group B receives an experimental treatment. The researcher expects the experimental treatment might reduce recovery time but wants to test for any difference. If $M_A$ and $M_B$ represent the median recovery times, what hypotheses should be tested?

$H_0: M_A = M_B$ ; $H_1: M_A ≠ M_B$ (correct answer)
$H_0: M_A ≤ M_B$ ; $H_1: M_A > M_B$
$H_0: M_A ≥ M_B$ ; $H_1: M_A < M_B$
$H_0: M_A - M_B = 0$ ; $H_1: M_A - M_B < 0$
$H_0: M_B ≤ M_A$ ; $H_1: M_B > M_A$

Explanation: When testing for differences between groups in biostatistics, the key decision is whether you're looking for any difference (two-tailed test) or a specific directional difference (one-tailed test). The question states the researcher "wants to test for any difference," which signals a two-tailed approach, even though there's an expectation about the direction. The correct hypotheses are those in option A:

H_0: M_A = M_B

and

H_1: M_A ≠ M_B

. The null hypothesis assumes no difference between median recovery times, while the alternative hypothesis tests for any difference in either direction. This two-tailed test is appropriate because the researcher wants to detect whether the experimental treatment performs differently from standard care, regardless of whether it's better or worse. Option B (

H_0: M_A ≤ M_B

;

H_1: M_A > M_B

) incorrectly assumes we're only testing whether standard care is worse than experimental treatment. Option C (

H_0: M_A ≥ M_B

;

H_1: M_A < M_B

) represents a one-tailed test in the expected direction, but this ignores the researcher's stated goal of testing for "any difference." Option D expresses the same hypotheses as A but in difference form rather than equality form—while mathematically equivalent, the equality format in A is the standard convention for stating hypotheses. Remember: when a question mentions testing for "any difference" or "whether groups differ," choose two-tailed hypotheses with equality in the null and inequality (≠) in the alternative, regardless of directional expectations mentioned.

Question 14

In a pharmacokinetic study, researchers want to establish that a new formulation of a drug is bioequivalent to the reference formulation. Regulatory guidelines require that the ratio of geometric means for AUC (area under the curve) be between 0.80 and 1.25. If R represents the ratio of geometric means (test/reference), what hypotheses should be tested for bioequivalence?

$H_0: R = 1.0$ ; $H_1: R ≠ 1.0$
$H_0: 0.80 ≤ R ≤ 1.25$ ; $H_1: R < 0.80$ or $R > 1.25$
$H_0: R < 0.80$ or $R > 1.25$ ; $H_1: 0.80 ≤ R ≤ 1.25$ (correct answer)
$H_0: R ≤ 0.80$ or $R ≥ 1.25$ ; $H_1: 0.80 < R < 1.25$
$H_0: |R - 1| ≥ 0.20$ ; $H_1: |R - 1| < 0.20$

Explanation: When you encounter bioequivalence testing questions, remember that this is fundamentally different from traditional hypothesis testing. Instead of trying to prove a difference exists, you're trying to prove that two formulations are equivalent within acceptable regulatory limits. In bioequivalence studies, you want to demonstrate that the test formulation performs similarly to the reference formulation. The regulatory requirement that the ratio R must fall between 0.80 and 1.25 defines the acceptable equivalence range. To prove bioequivalence, you must show that R falls within this range. The correct approach is option C:

H_0: R < 0.80

R > 1.25

;

H_1: 0.80 ≤ R ≤ 1.25

. This sets up the null hypothesis as "the formulations are NOT equivalent" (ratio falls outside acceptable limits) and the alternative hypothesis as "the formulations ARE equivalent" (ratio falls within acceptable limits). When you reject this null hypothesis, you conclude bioequivalence. Option A represents traditional superiority testing, which tests for any difference rather than equivalence. Option B incorrectly makes bioequivalence the null hypothesis—you can't "prove" a null hypothesis, only fail to reject it. Option D uses the wrong inequality symbols and doesn't properly represent the bioequivalence range. Remember this key principle: in bioequivalence testing, you must flip the traditional hypothesis structure. Set up your null hypothesis as "non-equivalence" so that rejecting it allows you to conclude equivalence with statistical confidence. This approach protects against falsely claiming bioequivalence when insufficient evidence exists.

Question 15

A researcher wants to test whether the correlation between two biomarkers is significantly different from zero, but is particularly interested in detecting positive correlations because they would support a specific biological theory. If ρ represents the population correlation coefficient, what hypothesis formulation best serves this research goal?

$H_0: ρ = 0$ ; $H_1: ρ ≠ 0$
$H_0: ρ ≤ 0$ ; $H_1: ρ > 0$ (correct answer)
$H_0: ρ ≥ 0$ ; $H_1: ρ < 0$
$H_0: ρ < 0$ ; $H_1: ρ ≥ 0$
$H_0: ρ > 0$ ; $H_1: ρ ≤ 0$

Explanation: When you encounter hypothesis testing questions about correlations, the key is matching your hypothesis formulation to your research interest. The researcher here specifically wants to detect positive correlations to support their biological theory, which signals you need a one-tailed test focused on the positive direction. The correct formulation is

H_0: ρ ≤ 0

and

H_1: ρ > 0

(option B). This setup allows the researcher to directly test for positive correlation while maintaining proper hypothesis structure. The null hypothesis includes zero and all negative values, while the alternative hypothesis captures exactly what the researcher hopes to find—a positive correlation that would support their theory. This one-tailed approach also provides more statistical power to detect positive correlations compared to a two-tailed test. Option A (

H_0: ρ = 0

;

H_1: ρ ≠ 0

) represents a two-tailed test that would detect any correlation different from zero, but doesn't focus on the researcher's specific interest in positive correlations and has less power for detecting them. Option C (

H_0: ρ ≥ 0

;

H_1: ρ < 0

) tests for negative correlations, which is opposite to the researcher's interest. Option D (

H_0: ρ < 0

;

H_1: ρ ≥ 0

) has an improper structure where the null hypothesis doesn't include the point of no effect (zero), making it unsuitable for standard hypothesis testing. Study tip: When the research question mentions a specific direction of interest (positive/negative correlation, increase/decrease), choose the one-tailed test that puts that direction of interest in the alternative hypothesis.

Question 16

A researcher wants to test whether the proportion of patients experiencing side effects from a new treatment differs from the historical rate of 0.15. However, the researcher is particularly concerned about the treatment being worse than historical controls. Which hypothesis formulation best reflects this research priority?

$H_0: p = 0.15$ ; $H_1: p ≠ 0.15$ (two-tailed test with α = 0.05)
$H_0: p ≤ 0.15$ ; $H_1: p > 0.15$ (one-tailed test with α = 0.05) (correct answer)
$H_0: p = 0.15$ ; $H_1: p > 0.15$ (one-tailed test with α = 0.05)
$H_0: p ≥ 0.15$ ; $H_1: p < 0.15$ (one-tailed test with α = 0.05)
$H_0: p = 0.15$ ; $H_1: p ≠ 0.15$ (two-tailed test with α = 0.025)

Explanation: When you encounter hypothesis testing questions involving safety concerns, the key is recognizing that the researcher's priorities should drive whether you use a one-tailed or two-tailed test and how you formulate the hypotheses. This researcher is "particularly concerned about the treatment being worse than historical controls" — meaning they're worried the side effect rate might be higher than 0.15. This concern suggests they want maximum power to detect an increase in side effects, which calls for a one-tailed test focused on detecting

p > 0.15

. The correct formulation is

H_0: p ≤ 0.15

and

H_1: p > 0.15

. The null hypothesis represents the "safe" scenario (side effects are no worse than historical), while the alternative captures the researcher's primary concern (side effects are worse). This setup maximizes statistical power to detect the problematic outcome. Option A uses a two-tailed test, which splits the alpha between both directions and reduces power to detect the specific concern about increased side effects. Option C has the right alternative hypothesis but uses

H_0: p = 0.15

instead of

H_0: p ≤ 0.15

— while this works mathematically, the inequality form in option B better represents the conceptual framework. Option D tests the wrong direction entirely, focusing on whether the treatment is better than historical controls. Study tip: In safety-focused biostatistics problems, identify what outcome the researcher is most worried about detecting. That concern becomes your alternative hypothesis, and choosing one-tailed versus two-tailed depends on whether you have a directional concern or just want to detect any difference.

Question 17

A pharmaceutical company claims their new pain medication provides relief for at least 80% of patients. A regulatory agency wants to test this claim before approving the drug. If p represents the true proportion of patients who experience relief, what hypotheses should the regulatory agency test?

$H_0: p ≥ 0.80$ ; $H_1: p < 0.80$ (correct answer)
$H_0: p = 0.80$ ; $H_1: p ≠ 0.80$
$H_0: p ≤ 0.80$ ; $H_1: p > 0.80$
$H_0: p < 0.80$ ; $H_1: p ≥ 0.80$
$H_0: p > 0.80$ ; $H_1: p ≤ 0.80$

Explanation: When you encounter hypothesis testing questions in biostatistics, you need to identify what claim is being tested and who has the burden of proof. Regulatory agencies are skeptical gatekeepers - they assume claims are false until proven true, which determines how you set up your hypotheses. The pharmaceutical company claims their drug works for "at least 80%" of patients. The regulatory agency's job is to be skeptical of this claim. In hypothesis testing, the null hypothesis (

H_0

) represents the status quo or the assumption we start with, while the alternative hypothesis (

H_1

) represents what we're trying to prove. From the agency's perspective, they assume the company's claim is true (

p ≥ 0.80

) unless they find strong evidence otherwise. They're looking for evidence that the drug is actually less effective than claimed. This makes option A correct:

H_0: p ≥ 0.80

and

H_1: p < 0.80

. Option B (

H_0: p = 0.80

;

H_1: p ≠ 0.80

) sets up a two-tailed test, but the agency specifically cares about whether the drug is less effective than claimed, not more effective. Option C reverses the hypotheses - it would test whether the drug is better than 80%, which isn't the regulatory concern. Option D has the company trying to prove their own claim, which isn't how regulatory testing works. Remember: In regulatory settings, the null hypothesis typically favors the claim being tested, and the alternative represents the regulatory concern (usually that the product doesn't work as claimed).

Question 18

A medical device company claims their new glucose meter has measurement bias within ±2 mg/dL of reference values across the physiological range. For regulatory submission, they must demonstrate this claim is true. If μ represents the mean bias, which hypothesis formulation places the appropriate burden of proof on the company?

$H_0: |\mu| \leq 2$ vs $H_a: |\mu| > 2$ (correct answer)
$H_0: |\mu| \geq 2$ vs $H_a: |\mu| < 2$
$H_0: -2 \leq \mu \leq 2$ vs $H_a: \mu < -2 \text{ or } \mu > 2$
$H_0: \mu = 0$ vs $H_a: |\mu| \leq 2$

Explanation: The company must demonstrate their device meets the ±2 mg/dL specification. The burden should be on them to show the bias is acceptable. The null should represent the unacceptable condition (bias exceeds limits), requiring evidence to reject it in favor of acceptability. Option A correctly structures this so rejecting the null demonstrates compliance. Option B makes it too easy by assuming the device is bad unless proven good, which isn't how regulatory approval works. Option C is mathematically equivalent to A but uses non-standard notation. Option D tests only for zero bias, not the ±2 mg/dL tolerance.

Question 19

A researcher is comparing the effectiveness of two different surgical procedures for treating a condition. Procedure A is the current standard, and Procedure B is a new technique. The researcher wants to determine if Procedure B has a different success rate than Procedure A, but will only recommend switching to Procedure B if it shows superior results. If $p_A$ and $p_B$ represent the success rates, how should the hypotheses be formulated for the recommendation decision?

$H_0: p_A = p_B$ ; $H_1: p_A ≠ p_B$
$H_0: p_B ≤ p_A$ ; $H_1: p_B > p_A$ (correct answer)
$H_0: p_B ≥ p_A$ ; $H_1: p_B < p_A$
$H_0: p_A - p_B = 0$ ; $H_1: p_A - p_B < 0$
$H_0: p_A < p_B$ ; $H_1: p_A ≥ p_B$

Explanation: When designing hypothesis tests for clinical decision-making, you must align your statistical framework with the practical decision you need to make. This question tests your understanding of directional hypotheses when there's a specific action threshold. The researcher will only recommend switching from Procedure A (current standard) to Procedure B if the new procedure shows superior results. This means you're not just testing whether the procedures are different—you're specifically testing whether Procedure B is better than Procedure A. This calls for a one-tailed test where the alternative hypothesis reflects the condition needed to take action. Answer B correctly sets up

H_0: p_B ≤ p_A

(Procedure B is not superior) versus

H_1: p_B > p_A

(Procedure B is superior). Rejecting the null hypothesis would provide evidence that Procedure B is better, justifying the recommendation to switch. Answer A uses a two-tailed test (

H_1: p_A ≠ p_B

), which would detect any difference but wouldn't specifically test for superiority. Finding that procedures differ doesn't tell you which is better. Answer C tests the wrong direction (

H_1: p_B < p_A

), asking whether Procedure B is worse—the opposite of what you need for a recommendation decision. Answer D, while mathematically equivalent to testing

p_B > p_A

, uses confusing notation (

p_A - p_B < 0

) that obscures the research question. Study tip: In clinical trials, always match your alternative hypothesis to the specific claim that would justify taking action. If you need evidence of superiority to recommend a change, use a one-tailed test in that direction.

Question 20

A clinical laboratory is validating a new assay and needs to demonstrate that the coefficient of variation (CV) is no more than 5% to meet regulatory standards. The validation will be expensive to repeat if the assay fails to meet this requirement. How should the hypotheses be structured?

$H_0: CV = 0.05$ vs $H_a: CV \neq 0.05$
$H_0: CV \leq 0.05$ vs $H_a: CV > 0.05$ (correct answer)
$H_0: CV \geq 0.05$ vs $H_a: CV < 0.05$
$H_0: CV > 0.05$ vs $H_a: CV \leq 0.05$

Explanation: The laboratory needs to demonstrate compliance with the standard (CV ≤ 5%). The burden should be on proving the assay is acceptable. The null should represent the unacceptable condition (CV too high), requiring evidence to reject it in favor of acceptability. Option B correctly structures this so that rejecting the null provides evidence the assay meets the standard. Option A tests only equality. Option C makes it too easy to 'prove' compliance by assuming the assay is good unless proven bad. Option D has an illogical null hypothesis that excludes the boundary value.